Abstract
Malignancy remains a life-threatening challenge worldwide. Although remarkable advances have been achieved in tumor immunotherapy, the therapeutic effects are unsatisfactory due to low immunogenicity and immunosuppressive tumor microenvironment. In this work, a phenylboronic acid-modified polymeric nano-prodrug based on β-cyclodextrin (β-CD) with chemical conjugation of shikonin (SK) and chloroquine (CQ) was developed for tumor immunotherapy. The nanoparticles demonstrate high tumor-targeting and penetrating capability, and efficient cellular uptake via the complex of phenylboronic acid and sialic acid on malignant cells. Subsequently, SK induced programmed cell death and immunogenicity in tumor cells. Noticeably, the introduction of CQ terminated autophagic flux initiated by SK and strengthened efficient antigen exposure. This led to dendritic cell (DC) activation, cytotoxic T lymphocyte infiltration, reduced immunosuppression within the tumor microenvironment, and decreased primary tumor burden and pulmonary metastasis. These data suggested that our carrier is a promising strategy to augment tumor immunogenicity and therapeutic efficiency against carcinoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
